{"attribute_content":[],"alternate_symbols":["MGA1"],"id":"10262","symbol":"IGS1","alternate_names":["MEGALOBLASTIC ANEMIA, FINNISH TYPE","Megaloblastic anemia 1, Finnish type"],"medgen_id":"C4016819","name":"Imerslund-Gräsbeck syndrome 1","xrefs":["{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEGALOBLASTIC ANEMIA, FINNISH TYPE\"}","{\"db\":\"OMIM\",\"id\":\"250950\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGA1\"}","{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGA1\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"imerslund-grasbeck-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"261100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Imerslund-Gräsbeck syndrome is a condition caused by low levels of vitamin B12 (also known as cobalamin). The primary feature of this condition is a blood disorder called megaloblastic anemia. In this form of anemia, which is a disorder characterized by the shortage of red blood cells, the red cells that are present are abnormally large. About half of people with Imerslund-Gräsbeck syndrome also have high levels of protein in their urine (proteinuria). Although proteinuria can be an indication of kidney problems, people with Imerslund-Gräsbeck syndrome appear to have normal kidney function.Imerslund-Gräsbeck syndrome typically begins in infancy or early childhood. The blood abnormality leads to many of the signs and symptoms of the condition, including an inability to grow and gain weight at the expected rate (failure to thrive), pale skin (pallor), excessive tiredness (fatigue), and recurring gastrointestinal or respiratory infections. Other features of Imerslund-Gräsbeck syndrome include mild neurological problems, such as weak muscle tone (hypotonia), numbness or tingling in the hands or feet, movement problems, delayed development, or confusion. Rarely, affected individuals have abnormalities of organs or tissues that make up the urinary tract, such as the bladder or the tubes that carry fluid from the kidneys to the bladder (the ureters).","type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["FADS"],"id":"1806","symbol":"FADS1","alternate_names":["Arthrogryposis multiplex congenita with pulmonary hypoplasia","FETAL AKINESIA DEFORMATION SEQUENCE 1","Lethal Pena-Shokeir 1 syndrome","Pena Shokeir syndrome, type 1"],"medgen_id":"C1276035","name":"Pena-Shokeir syndrome type I","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0100101\"}","{\"db\":\"OMIM\",\"id\":\"208150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"994\"}","{\"db\":\"OMIM\",\"id\":\"208150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FETAL AKINESIA DEFORMATION SEQUENCE 1\"}","{\"db\":\"OMIM\",\"id\":\"601296.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FETAL AKINESIA DEFORMATION SEQUENCE 1\"}","{\"db\":\"OMIM\",\"id\":\"601296.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FETAL AKINESIA DEFORMATION SEQUENCE 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pena+Shokeir+syndrome%2C+type+1/5655\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"401138005\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"208150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"9884","alternate_names":[],"medgen_id":"C4017076","name":"Systemic lupus erythematosus, association with susceptibility to, 10","xrefs":[],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"40075","symbol":"EIEE65","alternate_names":[],"medgen_id":"C4693925","name":"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 65","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0033374\"}","{\"db\":\"OMIM\",\"id\":\"618008\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"606323.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606323.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618008\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618008\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"5231","alternate_symbols":[],"id":"5920","symbol":"SFWHS","alternate_names":["Skin fragility woolly hair syndrome"],"medgen_id":"C1843292","name":"Skin fragility-woolly hair-palmoplantar keratoderma syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011882\"}","{\"db\":\"OMIM\",\"id\":\"607655\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293165\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Skin+fragility+woolly+hair+syndrome/6634\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Skin fragility woolly hair syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5231\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011882\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607655\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"3203","alternate_symbols":["BGMR","WSN"],"id":"3766","symbol":"WSMN","alternate_names":["BASAL GANGLION DISORDER WITH MENTAL RETARDATION","Basal ganglia disorder with mental retardation","Laxova Brown Hogan syndrome","Parkinsonism, early onset with mental retardation","X-linked recessive basal ganglia disorder with mental retardation"],"medgen_id":"C0796195","name":"Early-onset parkinsonism-intellectual disability syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010709\"}","{\"db\":\"OMIM\",\"id\":\"311510\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2379\"}","{\"db\":\"OMIM\",\"id\":\"311510\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BASAL GANGLION DISORDER WITH MENTAL RETARDATION\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinsonism%2C+early+onset+with+mental+retardation/5607\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinsonism, early onset with mental retardation\"}","{\"db\":\"OMIM\",\"id\":\"311510\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BGMR\"}","{\"db\":\"OMIM\",\"id\":\"311510\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WSN\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3203\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010709\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"311510\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"9287","alternate_names":["Leydig cell hypoplasia, partial"],"medgen_id":"C2673497","name":"Leydig cell hypoplasia, type II","xrefs":[],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"11904","alternate_symbols":[],"id":"43207","symbol":"CMAVM","alternate_names":[],"medgen_id":"C1842180","name":"Capillary malformation-arteriovenous malformation","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012016\"}","{\"db\":\"OMIM\",\"id\":\"PS608354\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"137667\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"11904\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Capillary+malformation-arteriovenous+malformation/7888\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS608354\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608354\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["BDB"],"id":"1053","symbol":"BDB1","alternate_names":["Type B brachydactyly"],"medgen_id":"C1862112","name":"Brachydactyly type B1","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005831\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007220\"}","{\"db\":\"OMIM\",\"id\":\"113000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93383\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005831\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Type B brachydactyly\"}","{\"db\":\"OMIM\",\"id\":\"113000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BDB\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brachydactyly+type+B1/7857\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007220\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"113000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"3050","symbol":"MSSE","alternate_names":["ESS1 (formerly)","Ferguson-Smith type epithelioma","MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO","Multiple self healing squamous epithelioma"],"medgen_id":"C4083047","name":"Familial keratoacanthoma","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018851\"}","{\"db\":\"OMIM\",\"id\":\"132800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"493\"}","{\"db\":\"Orphanet\",\"id\":\"65748\"}","{\"db\":\"OMIM\",\"id\":\"132800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"190181.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"190181.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"190181.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"190181.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+self+healing+squamous+epithelioma/4971\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Multiple self healing squamous epithelioma\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018851\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"132800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":["Hereditary cancer syndrome","Neoplasm"]}
{"attribute_content":[],"gard_id":"10471","alternate_symbols":["LGMDR7"],"id":"2990","symbol":"LGMD2G","alternate_names":["Limb-girdle muscular dystrophy, type 2G","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 7","Telethoninopathy"],"medgen_id":"C1866008","name":"Autosomal recessive limb-girdle muscular dystrophy type 2G","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011170\"}","{\"db\":\"OMIM\",\"id\":\"601954\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"34514\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Limb-girdle+muscular+dystrophy%2C+type+2G/4242\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Limb-girdle muscular dystrophy, type 2G\"}","{\"db\":\"OMIM\",\"id\":\"601954\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 7\"}","{\"db\":\"OMIM\",\"id\":\"604488.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 7\"}","{\"db\":\"OMIM\",\"id\":\"604488.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 7\"}","{\"db\":\"OMIM\",\"id\":\"601954\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMDR7\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10471\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011170\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"limb-girdle-muscular-dystrophy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601954\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Limb-girdle muscular dystrophy is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs. The muscles most affected are those closest to the body (proximal muscles), specifically the muscles of the shoulders, upper arms, pelvic area, and thighs.The severity, age of onset, and features of limb-girdle muscle dystrophy vary among the many subtypes of this condition and may be inconsistent even within the same family. Signs and symptoms may first appear at any age and generally worsen with time, although in some cases they remain mild.In the early stages of limb-girdle muscular dystrophy, affected individuals may have an unusual walking gait, such as waddling or walking on the balls of their feet, and may also have difficulty running. They may need to use their arms to press themselves up from a squatting position because of their weak thigh muscles. As the condition progresses, people with limb-girdle muscular dystrophy may eventually require wheelchair assistance.Muscle wasting may cause changes in posture or in the appearance of the shoulder, back, and arm. In particular, weak shoulder muscles tend to make the shoulder blades (scapulae) \"stick out\" from the back, a sign known as scapular winging. Affected individuals may also have an abnormally curved lower back (lordosis) or a spine that curves to the side (scoliosis). Some develop joint stiffness (contractures) that can restrict movement in their hips, knees, ankles, or elbows. Overgrowth (hypertrophy) of the calf muscles occurs in some people with limb-girdle muscular dystrophy.Weakening of the heart muscle (cardiomyopathy) occurs in some forms of limb-girdle muscular dystrophy. Some affected individuals experience mild to severe breathing problems related to the weakness of muscles needed for breathing. In some cases, the breathing problems are severe enough that affected individuals need to use a machine to help them breathe (mechanical ventilation).Intelligence is generally unaffected in limb-girdle muscular dystrophy; however, developmental delay and intellectual disability have been reported in rare forms of the disorder.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"7006","alternate_symbols":[],"id":"2837","alternate_names":["Enterocyte cobalamin malabsorption","Enterocyte intrinsic factor receptor, defect of","Imerslund-Grasbeck syndrome","Megaloblastic anemia due to inborn errors of metabolism","Pernicious anemia, juvenile, due to selective intestinal malabsorption of vitamin b12, with proteinuria"],"medgen_id":"C4551825","name":"Imerslund-Gräsbeck syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009853\"}","{\"db\":\"OMIM\",\"id\":\"PS261100\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"35858\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009853\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Imerslund-Grasbeck syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Megaloblastic+anemia+due+to+inborn+errors+of+metabolism/8803\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Megaloblastic anemia due to inborn errors of metabolism\"}","{\"db\":\"SNOMED CT\",\"id\":\"34925000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Megaloblastic anemia due to inborn errors of metabolism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7006\",\"ref_field\":\"gard_id\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"5742","symbol":"MDPT1","alternate_names":["Butterfly dystrophy of retinal pigment epithelium","Butterfly-shaped pigment dystrophy of the fovea","Macular dystrophy, butterfly-shaped pigmentary"],"medgen_id":"C4551999","name":"Macular dystrophy, patterned, 1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008210\"}","{\"db\":\"OMIM\",\"id\":\"169150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99001\"}","{\"db\":\"OMIM\",\"id\":\"169150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10312","alternate_symbols":[],"id":"4119","symbol":"SCPNK","alternate_names":["Kaeser syndrome","Scapuloperoneal syndrome, neurogenic type, of Kaeser","Stark-Kaeser syndrome"],"medgen_id":"C1867005","name":"Neurogenic scapuloperoneal syndrome, Kaeser type","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008407\"}","{\"db\":\"OMIM\",\"id\":\"181400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85146\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10312\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008407\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"181400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"2610","alternate_symbols":["PFHBIB"],"id":"4039","symbol":"PFHB1B","alternate_names":["Progressive familial heart block type 1B"],"medgen_id":"C1970298","name":"Progressive familial heart block type IB","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011474\"}","{\"db\":\"OMIM\",\"id\":\"604559\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"871\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Progressive+familial+heart+block+type+1B/5979\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Progressive familial heart block type 1B\"}","{\"db\":\"OMIM\",\"id\":\"604559\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PFHBIB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2610\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011474\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"progressive-familial-heart-block\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"604559\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Progressive familial heart block is a genetic condition that alters the normal beating of the heart. A normal heartbeat is controlled by electrical signals that move through the heart in a highly coordinated way. These signals begin in a specialized cluster of cells called the sinoatrial node (the heart's natural pacemaker) located in the heart's upper chambers (the atria). From there, a group of cells called the atrioventricular node carries the electrical signals to another cluster of cells called the bundle of His. This bundle separates into multiple thin spindles called bundle branches, which carry electrical signals into the heart's lower chambers (the ventricles). Electrical impulses move from the sinoatrial node down to the bundle branches, stimulating a normal heartbeat in which the ventricles contract slightly later than the atria.Heart block occurs when the electrical signaling is obstructed anywhere from the atria to the ventricles. In people with progressive familial heart block, the condition worsens over time: early in the disorder, the electrical signals are partially blocked, but the block eventually becomes complete, preventing any signals from passing through the heart. Partial heart block causes a slow or irregular heartbeat (bradycardia or arrhythmia, respectively), and can lead to the buildup of scar tissue (fibrosis) in the cells that carry electrical impulses. Fibrosis contributes to the development of complete heart block, resulting in uncoordinated electrical signaling between the atria and the ventricles and inefficient pumping of blood in the heart. Complete heart block can cause a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, fainting (syncope), or sudden cardiac arrest and death.Progressive familial heart block can be divided into type I and type II, with type I being further divided into types IA and IB. These types differ in where in the heart signaling is interrupted and the genetic cause. In types IA and IB, the heart block originates in the bundle branch, and in type II, the heart block originates in the atrioventricular node. The different types of progressive familial heart block have similar signs and symptoms.Most cases of heart block are not genetic and are not considered progressive familial heart block. The most common cause of heart block is fibrosis of the heart, which occurs as a normal process of aging. Other causes of heart block can include the use of certain medications or an infection of the heart tissue.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"9704","alternate_symbols":[],"id":"4394","symbol":"MRXSSD","alternate_names":["Intellectual deficit X-linked Siderius type","MENTAL RETARDATION, X-LINKED, SYNDROMIC, SIDERIUS TYPE","Mental retardation X-linked Siderius type","Siderius Hamel syndrome","Siderius X-linked mental retardation syndrome","X-linked mental retardation Hamel type"],"medgen_id":"C1846055","name":"Syndromic X-linked intellectual disability Siderius type","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010286\"}","{\"db\":\"OMIM\",\"id\":\"300263\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85287\"}","{\"db\":\"OMIM\",\"id\":\"300263\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, SYNDROMIC, SIDERIUS TYPE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Siderius+X-linked+mental+retardation+syndrome/6592\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Siderius X-linked mental retardation syndrome\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9704\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010286\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300263\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"2687","alternate_names":["LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM","LEYDIG CELL HYPOPLASIA, COMPLETE","Leydig cell agenesis"],"medgen_id":"C0266432","name":"Leydig cell hypoplasia, type 1","xrefs":["{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, COMPLETE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leydig+cells+hypoplasia/4217\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Leydig cell agenesis\"}","{\"db\":\"SNOMED CT\",\"id\":\"56212008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Leydig cell agenesis\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"8333","alternate_symbols":["BSAS"],"id":"4636","symbol":"ABDS","alternate_names":["Athabaskan brainstem dysgenesis","Bosley Salih Alorainy syndrome","Navajo brainstem syndrome"],"medgen_id":"C1832215","name":"Human HOXA1 syndromes","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011099\"}","{\"db\":\"OMIM\",\"id\":\"601536\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"69737\"}","{\"db\":\"Orphanet\",\"id\":\"69739\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Athabaskan+Brainstem+Dysgenesis/643\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Athabaskan brainstem dysgenesis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8333\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011099\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601536\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"40560","symbol":"MGRISCE2","alternate_names":[],"medgen_id":"C4748176","name":"MICROCEPHALY, GROWTH RESTRICTION, AND INCREASED SISTER CHROMATID EXCHANGE 2","xrefs":["{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"601243.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601243.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601243.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"292","symbol":"SPDRS","alternate_names":["GM3 SYNTHASE DEFICIENCY","SALT AND PEPPER MENTAL RETARDATION SYNDROME"],"medgen_id":"C1836824","name":"Salt and pepper developmental regression syndrome","xrefs":["{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171714\"}","{\"db\":\"Orphanet\",\"id\":\"370933\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GM3 SYNTHASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SALT AND PEPPER MENTAL RETARDATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"609056\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"9757","alternate_names":["Obesity, variation in"],"medgen_id":"C5193213","name":"PPARGC1B polymorphism","xrefs":[],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"9910","alternate_symbols":["LAEB"],"id":"5024","symbol":"EBLA","alternate_names":[],"medgen_id":"C1864826","name":"Lethal acantholytic epidermolysis bullosa","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012323\"}","{\"db\":\"OMIM\",\"id\":\"609638\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"158687\"}","{\"db\":\"OMIM\",\"id\":\"609638\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LAEB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9910\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012323\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609638\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"7186","alternate_symbols":[],"id":"2841","symbol":"NCMS","alternate_names":["NEUROCUTANEOUS MELANOSIS, SOMATIC","NEUROMELANOSIS","Neurocutaneous melanosis","Neurocutaneous melanosis syndrome"],"medgen_id":"C0544862","name":"Neurocutaneous melanocytosis","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009578\"}","{\"db\":\"OMIM\",\"id\":\"249400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2481\"}","{\"db\":\"OMIM\",\"id\":\"164790.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROCUTANEOUS MELANOSIS, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"164790.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROCUTANEOUS MELANOSIS, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"249400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROMELANOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neurocutaneous+melanosis/5161\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurocutaneous melanosis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7186\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009578\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"249400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"9709","alternate_names":[],"medgen_id":"CN068484","name":"Association with systemic lupus erythematosus","xrefs":[],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["GPHN"],"id":"1917","symbol":"CMNS","alternate_names":["Bathing trunk nevus","Congenital giant melanocytic nevus","Congenital giant pigmented nevus","Congenital melanocytic nevus - large","Giant hairy nevus","Giant pigmented hairy nevus","Giant pigmented mole","Giant pigmented nevus","MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC","PIGMENTED MOLES"],"medgen_id":"C1842036","name":"Large congenital melanocytic nevus","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005600\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005604\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0044792\"}","{\"db\":\"OMIM\",\"id\":\"137550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"626\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005600\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital giant melanocytic nevus\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Giant+Pigmented+Hairy+Nevus/3048\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Giant pigmented hairy nevus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005600\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Giant pigmented hairy nevus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005600\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Giant pigmented mole\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005600\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Giant pigmented nevus\"}","{\"db\":\"OMIM\",\"id\":\"164790.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"164790.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"164790.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MELANOCYTIC NEVUS SYNDROME, CONGENITAL, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"137550\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PIGMENTED MOLES\"}","{\"db\":\"OMIM\",\"id\":\"137550\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GPHN\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0044792\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"3531","alternate_symbols":[],"id":"1070","symbol":"BRNRS","alternate_names":["Monoamine oxidase A deficiency"],"medgen_id":"C0796275","name":"Brunner syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010379\"}","{\"db\":\"OMIM\",\"id\":\"300615\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3057\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Monoamine+oxidase+A+deficiency/4856\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Monoamine oxidase A deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3531\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010379\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300615\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"}]}"],"gard_id":"6400","alternate_symbols":[],"id":"1790","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"medgen_id":"C0002986","name":"Fabry disease","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","type":"Disease","keywords":[],"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A."}
{"attribute_content":[],"gard_id":"8598","alternate_symbols":["KIT"],"id":"2160","symbol":"GIST","content":"{\"Citation\":[{\"@Abbrev\":\"UK NEQAS, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"22685257\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EGTM, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23852704\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Gastrointestinal Stromal Sarcoma","Gastrointestinal stroma tumor","Gastrointestinal stromal tumor, somatic","Gastrointestinal stromal tumors"],"medgen_id":"C0238198","name":"Gastrointestinal stromal tumor","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100723\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011719\"}","{\"db\":\"MeSH\",\"id\":\"D046152\"}","{\"db\":\"OMIM\",\"id\":\"606764\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"44890\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100723\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Gastrointestinal stroma tumor\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100723\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Gastrointestinal stromal tumors\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8598\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Gastrointestinal+Stromal+Tumors/2997\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100723\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011719\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100723\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"606764\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":["Hereditary cancer syndrome"]}
{"attribute_content":[],"gard_id":"9174","alternate_symbols":["KRPPD","PARK9"],"id":"2530","symbol":"KRS","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23447832\",\"@Source\":\"PubMed\"},{\"$\":\"NBK121988\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","alternate_names":["PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET","Pallidopyramidal degeneration with supranuclear upgaze paresis, and dementia","Park 9","Parkinson disease 9"],"medgen_id":"C1847640","name":"Kufor-Rakeb syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011706\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"306674\"}","{\"db\":\"Orphanet\",\"id\":\"314632\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+9/5605\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinson disease 9\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KRPPD\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PARK9\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9174\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011706\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"1093","alternate_symbols":["HBBD","PFHBI","PFHBIA"],"id":"4024","symbol":"PFHB1A","content":"{\"Citation\":{\"@Abbrev\":\"HRS/EHRA/APHRS, 2013\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"23994779\",\"@Source\":\"PubMed\"}}}","alternate_names":["Cardiac conduction defect progressive","HEART BLOCK, PROGRESSIVE FAMILIAL, TYPE I","Heart block progressive familial type 1","Hereditary bundle branch system defect","PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA"],"medgen_id":"C1879286","name":"Progressive familial heart block, type 1A","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007240\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"871\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEART BLOCK, PROGRESSIVE FAMILIAL, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"600163.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"600163.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"600163.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"600163.0031\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HBBD\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PFHBI\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PFHBIA\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1093\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007240\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"113900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10108","alternate_symbols":[],"id":"3240","symbol":"CMS4C","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1168\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["CMS1d","Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency","Myasthenic syndrome, congenital, postsynaptic, associated with acetylcholine receptor deficiency","Myasthenic syndrome, congenital, type id"],"medgen_id":"C1837091","name":"Congenital myasthenic syndrome 4C","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012157\"}","{\"db\":\"OMIM\",\"id\":\"608931\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"590\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myasthenic+syndrome%2C+congenital%2C+associated+with+acetylcholine+receptor+deficiency/5000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10108\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012157\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1168\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608931\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Congenital myasthenic syndromes (designated as CMS throughout this entry) are characterized by fatigable weakness of skeletal muscle (e.g., ocular, bulbar, limb muscles) with onset at or shortly after birth or in early childhood; rarely, symptoms may not manifest until later in childhood. Cardiac and smooth muscle are usually not involved. Severity and course of disease are highly variable, ranging from minor symptoms to progressive disabling weakness. In some subtypes of CMS, myasthenic symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency may be precipitated by fever, infections, or excitement. Major findings of the neonatal-onset subtype include: respiratory insufficiency with sudden apnea and cyanosis; feeding difficulties; poor suck and cry; choking spells; eyelid ptosis; and facial, bulbar, and generalized weakness. Arthrogryposis multiplex congenita may also be present. Stridor in infancy may be an important clue to CMS. Later childhood-onset subtypes show abnormal muscle fatigability with difficulty in activities such as running or climbing stairs; motor milestones may be delayed; fluctuating eyelid ptosis and fixed or fluctuating extraocular muscle weakness are common presentations.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"4923","alternate_symbols":["SPPX2"],"id":"5933","symbol":"SPG2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301361\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1182\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["SPASTIC PARAPLEGIA 2, X-LINKED","Spastic paraplegia 2"],"medgen_id":"C1839264","name":"Hereditary spastic paraplegia 2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010733\"}","{\"db\":\"OMIM\",\"id\":\"312920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99015\"}","{\"db\":\"OMIM\",\"id\":\"312920\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 2, X-LINKED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+2/6686\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spastic paraplegia 2\"}","{\"db\":\"OMIM\",\"id\":\"312920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SPPX2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4923\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010733\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1182\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"312920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"PLP1 disorders of central nervous system myelin formation include a range of phenotypes from Pelizaeus-Merzbacher disease (PMD) to spastic paraplegia 2 (SPG2). PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment; the findings progress to severe spasticity and ataxia. Life span is shortened. SPG2 manifests as spastic paraparesis with or without CNS involvement and usually normal life span. Intrafamilial variation of phenotypes can be observed, but the signs are usually fairly consistent within families. Heterozygous females may manifest mild-to-moderate signs of the disease.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"9781","alternate_symbols":[],"id":"2613","symbol":"MRXSL","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301461\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1284\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Lubs X-linked mental retardation syndrome","MECP2 duplication syndrome","MENTAL RETARDATION, X-LINKED, SYNDROMIC, LUBS TYPE","MENTAL RETARDATION, X-LINKED, WITH RECURRENT RESPIRATORY INFECTIONS","Mental retardation, X-linked, Lubs type","XLMR syndrome, Lubs type"],"medgen_id":"C1846058","name":"Syndromic X-linked intellectual disability Lubs type","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010283\"}","{\"db\":\"OMIM\",\"id\":\"300260\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1762\"}","{\"db\":\"Genetic Alliance\",\"id\":\"MECP2+duplication+syndrome/4540\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MECP2 duplication syndrome\"}","{\"db\":\"OMIM\",\"id\":\"300260\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, SYNDROMIC, LUBS TYPE\"}","{\"db\":\"OMIM\",\"id\":\"300260\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, WITH RECURRENT RESPIRATORY INFECTIONS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9781\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010283\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1284\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300260\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"MECP2 duplication syndrome is a severe neurodevelopmental disorder characterized by early-onset hypotonia, feeding difficulty, gastrointestinal manifestations including gastroesophageal reflux and constipation, delayed psychomotor development leading to severe intellectual disability, poor speech development, progressive spasticity, recurrent respiratory infections (in ~75% of affected individuals), and seizures (in ~50%). MECP2 duplication syndrome is 100% penetrant in males. Occasionally females have been described with a MECP2 duplication and a range of findings from mild intellectual disability to a phenotype similar to that seen in males. In addition to the core features, autistic behaviors, nonspecific neuroradiologic findings on brain MRI, mottled skin, and urogenital anomalies have been observed in several affected boys.","type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"4274","symbol":"TMD","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301498\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1323\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Distal myopathy Markesbery-Griggs type","Tibial muscular dystrophy, tardive","UDD Myopathy","Udd Distal Myopathy"],"medgen_id":"C1838244","name":"Tibial muscular dystrophy","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010870\"}","{\"db\":\"OMIM\",\"id\":\"600334\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"609\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Distal+Myopathy+Markesbery-Griggs+Type/2304\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Distal myopathy Markesbery-Griggs type\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1323\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Udd Distal Myopathy\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010870\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1323\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600334\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Udd distal myopathy – tibial muscular dystrophy (UDM-TMD) is characterized by weakness of ankle dorsiflexion and inability to walk on the heels after age 30 years. Disease progression is slow and muscle weakness remains confined to the anterior compartment muscles for many years. The long toe extensors become clinically involved after ten to 20 years, leading to foot drop and clumsiness when walking. In the mildest form, UDM-TMD can remain unnoticed even in the elderly. EMG shows profound myopathic changes in the anterior tibial muscle, but preservation of the extensor brevis muscle. Muscle MRI shows selective fatty degeneration of the anterior tibial muscles and other anterior compartment muscles of the lower legs. Serum CK concentration may be normal or slightly elevated. Muscle biopsy shows progressive dystrophic changes in the tibialis anterior muscle with rimmed vacuoles at the early stages and replacement with adipose tissue at later stages of the disease.","type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"16751","symbol":"BBS16","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"medgen_id":"C3889474","name":"Bardet-Biedl syndrome 16","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014444\"}","{\"db\":\"OMIM\",\"id\":\"615993\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+syndrome+16/7800\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615993\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["IFT27"],"id":"32091","symbol":"BBS19","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"medgen_id":"C3889475","name":"Bardet-Biedl syndrome 19","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014447\"}","{\"db\":\"OMIM\",\"id\":\"615996\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"OMIM\",\"id\":\"615996\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"9594","symbol":"BBS15","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"medgen_id":"C3150127","name":"Bardet-Biedl syndrome 15","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014443\"}","{\"db\":\"OMIM\",\"id\":\"615992\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"OMIM\",\"id\":\"615992\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["HSN1"],"id":"3457","symbol":"HSAN1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301564\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1390\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["HSAN 1","HSN Type I","Hereditary Sensory Neuropathy Type I","Hereditary sensory neuropathy type 1","Neuropathy hereditary sensory radicular, autosomal dominant"],"medgen_id":"C0020071","name":"Hereditary sensory and autonomic neuropathy type 1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018213\"}","{\"db\":\"Orphanet\",\"id\":\"36386\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018213\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1390\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"162400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"SPTLC1-related hereditary sensory neuropathy (HSN) is an axonal form of hereditary motor and sensory neuropathy distinguished by prominent early sensory loss and later positive sensory phenomena including dysesthesia and characteristic \"lightning\" or \"shooting\" pains. Loss of sensation can lead to painless injuries, which, if unrecognized, result in slow wound healing and subsequent osteomyelitis requiring distal amputations. Motor involvement is present in all advanced cases and can be severe. After age 20 years, the distal wasting and weakness may involve proximal muscles, possibly leading to wheelchair dependency by the seventh or eighth decade. Sensorineural hearing loss is variable.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"1222","alternate_symbols":[],"id":"1353","symbol":"CLN4B","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301601\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1428\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Ceroid lipofuscinosis neuronal 4B autosomal dominant","Ceroid lipofuscinosis neuronal Parry type","DNAJC5-Related Neuronal Ceroid-Lipofuscinosis","Dominant form of adult neuronal ceroid-lipofuscinosis","Kufs disease autosomal dominant"],"medgen_id":"C1834207","name":"Neuronal ceroid lipofuscinosis 4B","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008083\"}","{\"db\":\"OMIM\",\"id\":\"162350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"228343\"}","{\"db\":\"Orphanet\",\"id\":\"79262\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ceroid+Lipofuscinosis+Neuronal+4B+Autosomal+Dominant/1255\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ceroid lipofuscinosis neuronal 4B autosomal dominant\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1222\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008083\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"162350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"9922","alternate_symbols":["HLH2","HPLH2"],"id":"5239","symbol":"FHL2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301617\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1444\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"medgen_id":"C1863727","name":"Familial hemophagocytic lymphohistiocytosis 2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011337\"}","{\"db\":\"OMIM\",\"id\":\"603553\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"540\"}","{\"db\":\"OMIM\",\"id\":\"603553\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HLH2\"}","{\"db\":\"OMIM\",\"id\":\"603553\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HPLH2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9922\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011337\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603553\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"6986","alternate_symbols":[],"id":"2648","symbol":"SPG1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301657\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1484\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Adducted thumb with mental retardation","Clasped thumb and mental retardation","Crash syndrome","Gareis-Mason syndrome","MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS","Mental Retardation Aphasia Shuffling Gait Adducted Thumbs (MASA)","SPASTIC PARAPLEGIA 1, X-LINKED","Spastic paraplegia 1","Thumb congenital clasped with mental retardation"],"medgen_id":"C0795953","name":"MASA syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010559\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2466\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, APHASIA, SHUFFLING GAIT, AND ADDUCTED THUMBS\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 1, X-LINKED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+1/6675\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spastic paraplegia 1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6986\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010559\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1484\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"303350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The phenotypic spectrum of L1 syndrome includes: X-linked hydrocephalus with stenosis of the aqueduct of Sylvius (HSAS); MASA syndrome (mental retardation [intellectual disability], aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs); SPG1 (X-linked complicated hereditary spastic paraplegia type 1); and X-linked complicated corpus callosum agenesis. Males with HSAS are born with severe hydrocephalus, adducted thumbs, and spasticity; intellectual disability is severe. In less severely affected males, hydrocephalus may be subclinically present and documented only because of developmental delay; intellectual disability ranges from mild (IQ: 50-70) to moderate (IQ: 30-50).","type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["JHF"],"id":"9509","symbol":"HFS","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301698\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1525\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["HYALINOSIS, SYSTEMIC","Hyalinosis, Inherited Systemic","Hyalinosis, systemic juvenile","Puretic syndrome"],"medgen_id":"C2745948","name":"Hyaline fibromatosis syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009229\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2028\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYALINOSIS, SYSTEMIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fibromatosis+Juvenile+Hyaline/2851\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1525\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"228600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Hyaline fibromatosis syndrome (HFS) is characterized by hyaline deposits in the papillary dermis and other tissues. It can present at birth or in infancy with severe pain with movement, progressive joint contractures, and often with severe motor disability, thickened skin, and hyperpigmented macules/patches over bony prominences of the joints. Gingival hypertrophy, skin nodules, pearly papules of the face and neck, and perianal masses are common. Complications of protein-losing enteropathy and failure to thrive can be life threatening. Cognitive development is normal. Many children with the severe form (previously called infantile systemic hyalinosis) have a significant risk of morbidity or mortality in early childhood; some with a milder phenotype (previously called juvenile hyaline fibromatosis) survive into adulthood.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"12963","alternate_symbols":["MEGDHEL","MGCA6"],"id":"17318","symbol":"MEGDEL","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24741715\",\"@Source\":\"PubMed\"},{\"$\":\"NBK195853\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["3-METHYLGLUTACONIC ACIDURIA WITH DYSTONIA-DEAFNESS, HEPATOPATHY, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME","3-METHYLGLUTACONIC ACIDURIA, TYPE VI","MEGDEL syndrome"],"medgen_id":"C3553597","name":"3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013875\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352328\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3-METHYLGLUTACONIC ACIDURIA WITH DYSTONIA-DEAFNESS, HEPATOPATHY, ENCEPHALOPATHY, AND LEIGH-LIKE SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3-METHYLGLUTACONIC ACIDURIA, TYPE VI\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MEGDHEL\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGCA6\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12963\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK195853\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614739\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The phenotypic spectrum of SERAC1 deficiency comprises MEGD(H)EL syndrome (3-methylglutaconic aciduria with deafness-dystonia, [hepatopathy], encephalopathy, and Leigh-like syndrome), juvenile-onset complicated hereditary spastic paraplegia (in 1 consanguineous family), and adult-onset generalized dystonia (in 1 adult male). MEGD(H)EL syndrome is characterized in neonates by hypoglycemia and a sepsis-like clinical picture for which no infectious agent can be found. During the first year of life feeding problems, failure to thrive, and/or truncal hypotonia become evident; many infants experience (transient) liver involvement ranging from undulating transaminases to prolonged hyperbilirubinemia and near-fatal liver failure. By age two years progressive deafness, dystonia, and spasticity prevent further psychomotor development and/or result in loss of acquired skills. Affected children are completely dependent on care for all activities of daily living; speech is absent.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10734","alternate_symbols":["PPB"],"id":"13889","symbol":"PPBFTDS","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24761742\",\"@Source\":\"PubMed\"},{\"$\":\"NBK196157\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["DICER1 syndrome","PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME"],"medgen_id":"C3839822","name":"DICER1-related pleuropulmonary blastoma cancer predisposition syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017288\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"284343\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PPB FAMILIAL TUMOR AND DYSPLASIA SYNDROME\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10734\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK196157\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"DICER1 tumor predisposition (DICER1) is characterized by an increased risk for pleuropulmonary blastoma (PPB), pulmonary cysts, thyroid gland neoplasia (multinodular goiter, adenomas, and/or thyroid cancer), ovarian tumors (Sertoli-Leydig cell tumor, gynandroblastoma, and sarcoma), and cystic nephroma. Less commonly observed tumors include ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma, pituitary blastoma, pineoblastoma, central nervous system (CNS) sarcoma, other CNS tumors, and presacral malignant teratoid tumor. The majority of tumors occur in individuals younger than age 40 years. PPB typically presents in infants and children younger than age six years. Ovarian sex cord-stromal tumors are most often diagnosed before age 40 years. Cystic nephroma generally presents in young children but has also been reported in adolescents. Additional clinical features that may be seen include macrocephaly, ocular abnormalities, structural anomalies of the kidney and collecting system, and dental anomalies (bulbous crowns).","type":"Disease","keywords":["hereditary cancer syndrome"]}
{"attribute_content":[],"alternate_symbols":[],"id":"9308","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"26425749\",\"@Source\":\"PubMed\"},{\"$\":\"NBK320989\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"medgen_id":"C1850599","name":"Leigh syndrome due to mitochondrial complex IV deficiency","xrefs":[],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"3860","symbol":"ISOD","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28933809\",\"@Source\":\"PubMed\"},{\"$\":\"NBK453433\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Sulfite oxidase deficiency","Sulfocysteinuria"],"medgen_id":"C2931746","name":"Isolated sulfite oxidase deficiency","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003643\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010089\"}","{\"db\":\"OMIM\",\"id\":\"272300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"833\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sulfite+oxidase+deficiency/6924\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sulfite oxidase deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003643\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sulfite oxidase deficiency\"}","{\"db\":\"SNOMED CT\",\"id\":\"367368009\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sulfite oxidase deficiency\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010089\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK453433\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"272300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The spectrum of isolated sulfite oxidase deficiency ranges from classic early-onset (severe) disease to late-onset (mild) disease. Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability. Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period. Children usually die during the first few months of life. Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia due to metabolic stroke. The clinical course may be progressive or episodic. In the episodic form encephalopathy, dystonia, choreoathetosis, and/or ataxia are intermittent.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"8553","alternate_symbols":["PKD/IC"],"id":"1556","symbol":"ICCA","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29334453\",\"@Source\":\"PubMed\"},{\"$\":\"NBK475803\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Convulsions, infantile, with paroxysmal choreoathetosis, familial","Infantile convulsions and paroxysmal choreoathetosis, familial","PAROXYSMAL KINESIGENIC DYSKINESIA WITH INFANTILE CONVULSIONS"],"medgen_id":"C1865926","name":"Infantile convulsions and choreoathetosis","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011178\"}","{\"db\":\"OMIM\",\"id\":\"602066\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"31709\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Infantile+convulsions+and+paroxysmal+choreoathetosis%2C+familial/3804\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Infantile convulsions and paroxysmal choreoathetosis, familial\"}","{\"db\":\"OMIM\",\"id\":\"602066\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PAROXYSMAL KINESIGENIC DYSKINESIA WITH INFANTILE CONVULSIONS\"}","{\"db\":\"OMIM\",\"id\":\"602066\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PKD/IC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8553\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011178\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK475803\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602066\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"PRRT2-associated paroxysmal movement disorders (PRRT2-PxMD) include paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), paroxysmal kinesigenic dyskinesia with infantile convulsions (PKD/IC), and hemiplegic migraine (HM). In addition, PRRT2 pathogenic variants have been identified in other childhood-onset movement disorders and different types of seizures, suggesting that the understanding of the spectrum of PRRT2-PxMD is still evolving. The paroxysmal attacks in PKD are characterized by dystonia, choreoathetosis, and less commonly ballismus. The seizures of BFIE are usually focal with or without generalization. Thirty percent of PRRT2-associated PKD is associated with BFIE and is referred to as PKD/IC.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10351","alternate_symbols":[],"id":"4438","symbol":"SCA6","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301319\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1140\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","alternate_names":[],"medgen_id":"C0752124","name":"Spinocerebellar ataxia type 6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008457\"}","{\"db\":\"OMIM\",\"id\":\"183086\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98758\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10351\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008457\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1140\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"183086\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The age of onset ranges from 19 to 73 years; mean age of onset is between 43 and 52 years. Initial symptoms are gait unsteadiness, stumbling, and imbalance (in ~90%) and dysarthria (in ~10%). Eventually all persons have gait ataxia, upper-limb incoordination, intention tremor, and dysarthria. Dysphagia and choking are common. Visual disturbances may result from diplopia, difficulty fixating on moving objects, horizontal gaze-evoked nystagmus, and vertical nystagmus. Hyperreflexia and extensor plantar responses occur in up to 40%-50%. Basal ganglia signs, including dystonia and blepharospasm, occur in up to 25%. Mentation is generally preserved.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"8310","alternate_symbols":["DM"],"id":"1131","symbol":"DM1","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301344\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1165\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG DM1 Guidelines, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19546810\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Orphanet, 2013\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Steinert myotonic dystrophy, 2013\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_SteinertMyotonicDystrophy-enPro77.pdf\"}},{\"@Abbrev\":\"EMQN, 2008\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"EMQN Best Practice Guidelines and Recommendations on Myotonic Dystrophy types 1 and 2\"},\"URL\":{\"$\":\"http://www.emqn.org/emqn/digitalAssets/0/444_DM-BPG_april2010.pdf\"}}]}","alternate_names":["Dystrophia myotonica type 1","Myotonic dystrophy type 1","Steinert disease","Steinert myotonic dystrophy","Steinert's disease"],"medgen_id":"C3250443","name":"Steinert myotonic dystrophy syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008056\"}","{\"db\":\"OMIM\",\"id\":\"160900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"273\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008056\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Myotonic dystrophy type 1\"}","{\"db\":\"OMIM\",\"id\":\"160900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8310\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myotonic+dystrophy+type+1/5078\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"77956009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1165\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"160900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Myotonic dystrophy type 1 (DM1) is a multisystem disorder that affects skeletal and smooth muscle as well as the eye, heart, endocrine system, and central nervous system. The clinical findings, which span a continuum from mild to severe, have been categorized into three somewhat overlapping phenotypes: mild, classic, and congenital. Mild DM1 is characterized by cataract and mild myotonia (sustained muscle contraction); life span is normal. Classic DM1 is characterized by muscle weakness and wasting, myotonia, cataract, and often cardiac conduction abnormalities; adults may become physically disabled and may have a shortened life span. Congenital DM1 is characterized by hypotonia and severe generalized weakness at birth, often with respiratory insufficiency and early death; intellectual disability is common.","type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10204","alternate_symbols":[],"id":"8917","symbol":"BBS5","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C3892039","name":"Bardet-Biedl syndrome 5","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014434\"}","{\"db\":\"OMIM\",\"id\":\"615983\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10204\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+5/731\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615983\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"823","alternate_symbols":[],"id":"8916","symbol":"BBS4","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C2936864","name":"Bardet-Biedl syndrome 4","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014433\"}","{\"db\":\"OMIM\",\"id\":\"615982\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"823\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+4/730\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615982\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":["MKS1"],"id":"8925","symbol":"BBS13","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C2673873","name":"Bardet-Biedl syndrome 13","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014441\"}","{\"db\":\"OMIM\",\"id\":\"615990\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"OMIM\",\"id\":\"615990\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10210","alternate_symbols":[],"id":"8923","symbol":"BBS11","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859569","name":"Bardet-Biedl syndrome 11","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014439\"}","{\"db\":\"OMIM\",\"id\":\"615988\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10210\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+11/726\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615988\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10209","alternate_symbols":[],"id":"8922","symbol":"BBS10","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859568","name":"Bardet-Biedl syndrome 10","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014438\"}","{\"db\":\"OMIM\",\"id\":\"615987\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10209\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+10/725\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615987\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10208","alternate_symbols":[],"id":"8921","symbol":"BBS9","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859567","name":"Bardet-Biedl syndrome 9","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014437\"}","{\"db\":\"OMIM\",\"id\":\"615986\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10208\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+9/735\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615986\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"alternate_symbols":[],"id":"8926","symbol":"BBS14","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C2673874","name":"Bardet-Biedl syndrome 14","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014442\"}","{\"db\":\"OMIM\",\"id\":\"615991\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"OMIM\",\"id\":\"615991\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10206","alternate_symbols":[],"id":"8919","symbol":"BBS7","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859565","name":"Bardet-Biedl syndrome 7","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014435\"}","{\"db\":\"OMIM\",\"id\":\"615984\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10206\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+7/733\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615984\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"6866","alternate_symbols":[],"id":"376","symbol":"BBS","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C0752166","name":"Bardet-Biedl syndrome","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015229\"}","{\"db\":\"OMIM\",\"id\":\"PS209900\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6866\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome/723\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"bardet-biedl-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS209900\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"5619004\",\"ref_field\":\"name\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10211","alternate_symbols":[],"id":"8924","symbol":"BBS12","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859570","name":"Bardet-Biedl syndrome 12","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014440\"}","{\"db\":\"OMIM\",\"id\":\"615989\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10211\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+12/727\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615989\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10207","alternate_symbols":[],"id":"8920","symbol":"BBS8","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1859566","name":"Bardet-Biedl syndrome 8","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014436\"}","{\"db\":\"OMIM\",\"id\":\"615985\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10207\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+8/734\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615985\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"10205","alternate_symbols":[],"id":"8918","symbol":"BBS6","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C1858054","name":"Bardet-Biedl syndrome 6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011523\"}","{\"db\":\"OMIM\",\"id\":\"605231\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10205\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+6/732\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"605231\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","keywords":[]}
{"attribute_content":[],"gard_id":"6299","alternate_symbols":["DKCA"],"id":"4974","symbol":"DKCA1","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301779\",\"@Source\":\"PubMed\"},{\"$\":\"NBK22301\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21610750\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Dyskeratosis congenita Scoggins type","Dyskeratosis congenita autosomal dominant"],"medgen_id":"C4551974","name":"Dyskeratosis congenita, autosomal dominant 1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007485\"}","{\"db\":\"OMIM\",\"id\":\"127550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1775\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dyskeratosis+Congenita+Autosomal+Dominant/2383\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dyskeratosis congenita autosomal dominant\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6299\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007485\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK22301\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"127550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Dyskeratosis congenita (DC), a telomere biology disorder, is characterized by a classic triad of dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck, and oral leukoplakia. The classic triad may not be present in all individuals. People with DC are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis. Other findings can include: abnormal pigmentation changes not restricted to the upper chest and neck, eye abnormalities (epiphora, blepharitis, sparse eyelashes, ectropion, entropion, trichiasis), and dental abnormalities (caries, periodontal disease, taurodauntism). Although most persons with DC have normal psychomotor development and normal neurologic function, significant developmental delay is present in the two variants in which additional findings include cerebellar hypoplasia (Hoyeraal Hreidarsson syndrome) and bilateral exudative retinopathy and intracranial calcifications (Revesz syndrome). Onset and progression of manifestations of DC vary: at the mild end of the spectrum are those who have only minimal physical findings with normal bone marrow function, and at the severe end are those who have the diagnostic triad and early-onset BMF.","type":"Disease","mode_of_inheritance":"Variable","keywords":["Neoplasm"]}
{"attribute_content":[],"gard_id":"2007","alternate_symbols":["DKC"],"id":"1509","symbol":"DKCX","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301779\",\"@Source\":\"PubMed\"},{\"$\":\"NBK22301\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21610750\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Zinsser-Cole-Engman Syndrome"],"medgen_id":"C1148551","name":"Dyskeratosis congenita, X-linked","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010584\"}","{\"db\":\"OMIM\",\"id\":\"305000\",\"type\":\"MIM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2007\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010584\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK22301\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"305000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"Dyskeratosis congenita (DC), a telomere biology disorder, is characterized by a classic triad of dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck, and oral leukoplakia. The classic triad may not be present in all individuals. People with DC are at increased risk for progressive bone marrow failure (BMF), myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), solid tumors (usually squamous cell carcinoma of the head/neck or anogenital cancer), and pulmonary fibrosis. Other findings can include: abnormal pigmentation changes not restricted to the upper chest and neck, eye abnormalities (epiphora, blepharitis, sparse eyelashes, ectropion, entropion, trichiasis), and dental abnormalities (caries, periodontal disease, taurodauntism). Although most persons with DC have normal psychomotor development and normal neurologic function, significant developmental delay is present in the two variants in which additional findings include cerebellar hypoplasia (Hoyeraal Hreidarsson syndrome) and bilateral exudative retinopathy and intracranial calcifications (Revesz syndrome). Onset and progression of manifestations of DC vary: at the mild end of the spectrum are those who have only minimal physical findings with normal bone marrow function, and at the severe end are those who have the diagnostic triad and early-onset BMF.","type":"Disease","keywords":["Hereditary cancer syndrome"]}
{"attribute_content":[],"gard_id":"10096","alternate_symbols":["LRCC","MCL","MCUL","MCUL1"],"id":"5392","symbol":"HLRCC","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301430\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1252\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCRNC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24319509\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Cutaneous leiomyomata with uterine leiomyomata","Leiomyoma, hereditary multiple, of skin","Leiomyoma, multiple cutaneous","MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATA 1, WITH OR WITHOUT RENAL CELL CARCINOMA","Multiple cutaneous and uterine leiomyomata","Multiple cutaneous and uterine leiomyomatosis","Multiple cutaneous leiomyomas","Reed syndrome"],"medgen_id":"C1708350","name":"Hereditary leiomyomatosis and renal cell cancer","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007437\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007888\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"523\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE CUTANEOUS AND UTERINE LEIOMYOMATA 1, WITH OR WITHOUT RENAL CELL CARCINOMA\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007437\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Multiple cutaneous leiomyomas\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LRCC\"}","{\"db\":\"OMIM\",\"id\":\"605839\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LRCC\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCL\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCUL1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500895\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501395\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501397\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501538\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501539\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508575\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520030\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528532\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10096\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leiomyomatosis+and+renal+cell+cancer%2C+hereditary/4161\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007888\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1252\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"150800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"605839\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"FH tumor predisposition syndrome is characterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), and/or renal tumors. Pheochromocytoma and paraganglioma have also been described in a small number of families. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 30 years, increasing in size and number with age. Uterine leiomyomata tend to be numerous and large; age at diagnosis ranges from 18 to 53 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors are usually unilateral, solitary, and aggressive. They are associated with poor survival due to clinical aggressiveness and propensity to metastasize despite small primary tumor size. The median age of detection is approximately age 40 years.","disease_mechanism_id":"273","type":"Disease","keywords":[],"disease_mechanism":"loss of function"}
{"attribute_content":[],"gard_id":"10773","alternate_symbols":["HH5"],"id":"5355","symbol":"KAL5","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301509\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1334\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["CHD7-Related Isolated Gonadotropin-Releasing Hormone (GnRH) Deficiency","HYPOGONADOTROPHIC HYPOGONADISM 5 WITHOUT ANOSMIA","HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA","Kallmann syndrome 5"],"medgen_id":"C3552553","name":"Hypogonadotropic hypogonadism 5 with or without anosmia","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012880\"}","{\"db\":\"OMIM\",\"id\":\"612370\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"478\"}","{\"db\":\"OMIM\",\"id\":\"608892.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPHIC HYPOGONADISM 5 WITHOUT ANOSMIA\"}","{\"db\":\"OMIM\",\"id\":\"608892.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA\"}","{\"db\":\"OMIM\",\"id\":\"608892.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGONADOTROPIC HYPOGONADISM 5 WITH ANOSMIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kallmann+syndrome+5/8704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kallmann syndrome 5\"}","{\"db\":\"OMIM\",\"id\":\"612370\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HH5\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000334133\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556729\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556733\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558347\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10773\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012880\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1334\",\"ref_field\":\"public_definition\"}"],"public_definition":"Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., \u003c4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.","disease_mechanism_id":"273","type":"Disease","keywords":[],"disease_mechanism":"loss of function"}
{"attribute_content":[],"alternate_symbols":["FTDU","FTLDU"],"id":"5167","symbol":"HDDD","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301545\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1371\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20298421\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Dementia, hereditary dysphasic disinhibition","FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, GRN-RELATED","FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS","FTLD-TDP, GRN-RELATED","Frontotemporal dementia, ubiquitin-positive","GRN-Related Frontotemporal Dementia"],"medgen_id":"C1843792","name":"Grn-related frontotemporal lobar degeneration with Tdp43 inclusions","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011842\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"100070\"}","{\"db\":\"Orphanet\",\"id\":\"282\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL DEMENTIA WITH TDP43 INCLUSIONS, GRN-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"138945.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"138945.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FTLD-TDP, GRN-RELATED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Frontotemporal+Dementia%2C+Ubiquitin-Positive/2945\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Frontotemporal dementia, ubiquitin-positive\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1371\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRN-Related Frontotemporal Dementia\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FTDU\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FTLDU\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530102\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551442\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"grn-related-frontotemporal-lobar-degeneration\",\"ref_field\":\"ghr_links\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011842\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1371\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607485\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"public_definition":"The spectrum of GRN frontotemporal dementia (GRN-FTD) includes the behavioral variant (bvFTD), primary progressive aphasia (PPA; further subcategorized as progressive non-fluent aphasia [PNFA] and semantic dementia [SD]), and movement disorders with extrapyramidal features such as parkinsonism and corticobasal syndrome (CBS). A broad range of clinical features both within and between families is observed. The age of onset ranges from 35 to 87 years. Behavioral disturbances are the most common early feature, followed by progressive aphasia. Impairment in executive function manifests as loss of judgment and insight. In early stages, PPA often manifests as deficits in naming, word finding, or word comprehension. In late stages, affected individuals often become mute and lose their ability to communicate. Early findings of parkinsonism include rigidity, bradykinesia or akinesia (slowing or absence of movements), limb dystonia, apraxia (loss of ability to carry out learned purposeful movements), and disequilibrium. Late motor findings may include myoclonus, dysarthria, and dysphagia. Most affected individuals eventually lose the ability to walk. Disease duration is three to 12 years.","disease_mechanism_id":"273","type":"Disease","ghr_links":"GRN-related frontotemporal lobar degeneration","keywords":[],"disease_mechanism":"loss of function"}
{"attribute_content":[],"gard_id":"820","alternate_symbols":[],"id":"6540","symbol":"BBS1","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","alternate_names":[],"medgen_id":"C2936862","name":"Bardet-Biedl syndrome 1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008854\"}","{\"db\":\"OMIM\",\"id\":\"209900\",\"type\":\"MIM\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500417\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506625\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511130\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"820\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+1/724\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"209900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"273","type":"Disease","keywords":[],"disease_mechanism":"loss of function"}
{"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000323271\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000525921\"}]}"],"gard_id":"10815","alternate_symbols":["F2"],"id":"24727","symbol":"THPH1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301327\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1148\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["Blood clot in vein","Prothrombin-Related Thrombophilia (Factor II)","THROMBOPHILIA DUE TO FACTOR 2 DEFECT","Thrombophilia","Thrombosis susceptibility"],"medgen_id":"C3160733","name":"Venous thrombosis","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008559\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Blood clot in vein\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO FACTOR 2 DEFECT\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thrombophilia/7086\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Thrombophilia\"}","{\"db\":\"SNOMED CT\",\"id\":\"234467004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Thrombophilia\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500305\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"F2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025288\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000174333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321099\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331922\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332126\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502122\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502510\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503192\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507481\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509249\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511144\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520078\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521336\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521660\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531243\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556387\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10815\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism_id":"274","type":"Finding","keywords":[],"disease_mechanism":"gain of function"}
